Q1 #Novacyt "reiterating the £100 million revenue guidance for the full year, excluding DHSC, and we’re feeling confident about that number"
"see a growing private testing market & we also expect overall demand to increase as we head into the winter"
Q2 - "Unfortunately, we have no update on the dispute with the DHSC regarding the second supply contract, with no further news since the disclosure in June this year. Both sides are bound by confidentiality clause of the contract" #Novacyt#ALNOV
AGM Resolution 6.
Company seeks approval for facility to buy back up to 10% of company shares up to a value of €12
2020 Clause limiting buy back to max of €200k has been removed
“The new LightCycler® Nano Instrument delivers proven high quality at an affordable price & expands our qPCR business into a new segment. Customers will love the smart design of the instrument & appreciate the high quality data they can produce with it.”
👇 Wrong:
"So in essence if you look you will not find a document (that I have ever seen) saying Exsig formally passed its in service trial in relation to the contract whereas you will find one for Promate"
For supposed researched person, he's lazy. His thesis called out #Novacyt's 3rd party manufacturing for lowering margins
#ALNOV "invests in infrastructure to bring previously outsourced work in-house & to drive further automation, leading to improved margins & process controls"
#Mirriad "partnership comes at a time when consumers increasingly avoid ads & are becoming incredibly hard to reach & connect with. Brands need to become a deeply engaging part of peoples' experiences in new & radical ways"